Key Takeaways
Shares of Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) plunged nearly 7% after the company announced two of its directors are under investigation by China’s top securities regulator.
The board of directors believes the group's business operations remain normal and that the investigation will not affect day-to-day activities, the company said in a disclosure. Both executives said they will cooperate fully with regulators.
The China Securities Regulatory Commission (CSRC) placed Chairman Ye Xiaoping and director Cao Xiaochun, both controlling shareholders, under investigation for suspected violations of information disclosure laws regarding their shareholding changes. Following the announcement, Tigermed’s stock opened 6.58% lower at HKD 35.52 in Hong Kong trading.
The probe introduces significant governance uncertainty for the clinical research services provider, spooking investors despite the board's assurances of operational continuity. The decline puts the stock under pressure, and investors will be watching for required updates from the company on the CSRC’s findings.
This article is for informational purposes only and does not constitute investment advice.
